DRUG Bright Minds Biosciences (DRUG) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001827401
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
68
13F, latest reported quarter
Bright Minds Biosciences insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for BRIGHT MINDS BIOSCIENCES INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 4, 2024.
- The trade is 11.5% of the 950,000 shares held after it.
- No other insider sold within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Cormorant Asset Management, LP sold about $9.8M of DRUG on Apr 28, 2026, the largest insider sale at the company on our record; 68 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 17.4% of the 1,059,331 shares held after it.
- 1 other insider bought within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Cormorant Asset Management, LP bought about $4.0M of DRUG on Nov 4, 2024, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 68 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Oct 15, 2024.
- The trade is 0.8% of the 871,893 shares held after it.
- 1 other insider bought within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Cormorant Global Healthcare Master Fund, LP bought about $171.8K of DRUG on Oct 16, 2024; 1 other insider bought within 30 days and 68 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Oct 15, 2024.
- The trade is 0.4% of the 875,000 shares held after it.
- 1 other insider bought within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Cormorant Global Healthcare Master Fund, LP bought about $78.4K of DRUG on Oct 16, 2024; 1 other insider bought within 30 days and 68 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Oct 15, 2024.
- The trade is 4.6% of the 864,743 shares held after it.
- 1 other insider bought within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Cormorant Global Healthcare Master Fund, LP bought about $922.8K of DRUG on Oct 16, 2024; 1 other insider bought within 30 days and 68 funds added in the latest 13F quarter.13 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
68 funds bought in last quarter
more than 55% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
13.1% of the float short (float per yahoo 2026-10-26) · 8.5 days to cover · settled 2026-09-30
more than 93% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch DRUG
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-14.7%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns DRUG: institutional holders (13F)
13F holdings, latest reported quarter
1,349,107 sh
$94.8M
900,000 sh
$63.2M
686,184 sh
$48.2M
557,172 sh
$39.1M
545,000 sh
$38.3M
Congress trades in DRUG
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
DRUG planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
DRUG mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
AdvisorShares Psychedelics ETF
$1.7M position · as of 2026-06-30
3.8%
Eventide Healthcare & Life Sciences Fund
$9.1M position · as of 2026-06-30
0.5%
Driehaus Micro Cap Growth Fund
$2.9M position · as of 2026-06-30
0.5%
Goldman Sachs Small Cap Growth Insights Fund
$859.3K position · as of 2026-07-31
0.3%
Adara Smaller Companies Fund
$1.8M position · as of 2026-05-31
0.2%
Small Company Growth Portfolio
$39.7K position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 68 funds added last quarter. Each figure is a federal filing, dated the day it went public.
DRUG financials
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2024-09 | 2023-09 | 2022-09 | 2021-09 | |
|---|---|---|---|---|
| Net income | -$2.8M | -$7.4M | -$15.0M | -$8.7M |
SEC XBRL, fiscal years, as known on 2026-10-28
DRUG Stock Sonar score 2/7 axes
Find similar shapesCompare2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
